Articles tagged "Outcome"

2022 American Transplant Congress
Immunomodulation in Lung Transplant May Facilitate Transformation of Usual Interstitial Pneumonia Into Pleuroparenchymal Fibroelastosis
Q. Cai¹, K. Batra², J. R. Torrealba¹
¹Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, ²Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX
*Purpose: Pleuroparenchymal fibroelastosis (PPFE) is a rare but distinctive manifestation of interstitial lung disease (ILD) characterized by a highly elastotic pattern of lung fibrosis. Its…
2022 American Transplant Congress
Very Small Pediatric Donors May Help Address the Sex Disparity in Access to Kidney Transplantation
J. Yu, J. Sageshima, M. Nuño, N. Mineyev, N. Goussous, R. Perez
UC Davis Medical Center, Sacramento, CA
*Purpose: Women with end-stage renal disease have lower access to deceased donor kidney transplantation than men. Expanding the donor pool to include kidneys from very…
2022 American Transplant Congress
Prospective Evaluation of Donor-Derived Cell-Free DNA (dd-cfDNA) in Monitoring Response to Anti-Rejection Treatment in Kidney Transplant Recipients with Indication Biopsy
L. Benning¹, A. Fink², F. Kälble¹, C. Speer¹, C. Nusshag¹, M. Zeier¹, C. Süsal³, C. Morath¹, T. Tran²
¹Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany, ²Transplantation Immunology, Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany, ³Transplant Immunology Research Center of Excellence, Koç University Hospital, Istanbul, Turkey
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a marker of allograft injury in kidney transplant recipients (KTR). Little is known about the possible use of dd-cfDNA…
2022 American Transplant Congress
Evaluation of a Change in Pharmacy Discharge Medication Education for Kidney Transplant Recipients
M. Borsh¹, M. Leick¹, A. Donovan², C. McAdam-Marx², M. Keck¹
¹Pharmacy, Nebraska Medicine, Omaha, NE, ²College of Pharmacy, University of Nebraska Medical Center, Omaha, NE
*Purpose: To evaluate if modification of pharmacy discharge education for kidney transplant recipients contributed to a decreased length of hospital stay (LOS) post-transplant.*Methods: This was…
2022 American Transplant Congress
Mycophenolate Mofetil-Related Diarrhea and Beta-Glucuronidase Activity Following Kidney Transplantation
G. C. Onyeaghala¹, S. Elmer¹, D. Schladt¹, P. Yang¹, M. Wagner², L. Teigen², M. Al-Kofahi², B. Wu², W. Guan², C. Staley², S. Riad², A. Matas³, R. Remmel², W. Oetting², C. R. Dorr¹, P. Jacobson⁴, A. Israni¹
¹Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³University of Minnesota Medical School, Minneapolis, MN, ⁴Univ of MN, College of Pharmacy, Minneapolis, MN
*Purpose: The treatment of mycophenolate mofetil (MMF)-related diarrhea in kidney transplants recipients often involves dose reductions, which may result in less effective immunosuppression. We hypothesize…
2022 American Transplant Congress
Longitudinal Mortality Risks and Renal Functional Outcomes in Living Kidney Donors
K. Hotta¹, T. Osawa¹, I. Yokota², T. Inao², T. Tanabe¹, N. Iwahara¹, N. Shinohara¹
¹Urology, Hokkaido University Hospital, Sapporo, Japan, ²Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
*Purpose: Previous studies have suggested that living kidney donors do not have a higher risk of death or end-stage kidney disease (ESKD) than the general…
2022 American Transplant Congress
Living Related Kidney Donation for Alport Syndrome Spectrum: Long-Term Outcomes
Y. Caliskan¹, A. B. Dirim², S. Safak², B. Yelken³, A. Velioglu⁴, A. Yildiz⁵, O. A. Oto², N. Guller², H. Yazici², A. Ersoy⁵, A. Turkmen³, K. L. Lentine¹
¹Saint Louis University, Saint Louis, MO, ²Istanbul University, Istanbul, Turkey, ³Koc University Hospital, Istanbul, Turkey, ⁴Marmara University, Istanbul, Turkey, ⁵Uludag University, Bursa, Turkey
*Purpose: Data to guide the evaluation of living related donor (LRD) candidates for kidney transplant recipients with Alport syndrome (AS) spectrum are limited. We examined…
2022 American Transplant Congress
Transplant Coordinator Time Saved (TCTS) Through a Hybrid On Call Team for Deceased Donor Kidney and Pancreas Transplant Organ Offers
K. Ko, C. Gregory, J. Le, A. Lutrick, U. Reddy
Division of Kidney and Pancreas Transplantation, UC Irvine, Orange, CA
*Purpose: The purpose of this analysis was to estimate transplant coordinator time saved (TCTS) through the implementation of a hybrid on call team. Historically, transplant…
2022 American Transplant Congress
Evaluation of Diabetes-Free Life Expectancy Among Living Kidney Donors and Non-Donors with Obesity: A Longitudinal Cohort Study
C. Killian¹, R. Reed¹, M. McLeod¹, P. MacLennan¹, V. Kumar¹, S. Brooks¹, A. Maynor¹, L. Stanford¹, G. Baker¹, C. Schinstock², J. Silkensen³, G. Roll⁴, D. Segev⁵, B. Orandi¹, C. Lewis¹, J. Locke¹
¹University of Alabama at Birmingham, Birmingham, AL, ²Mayo Clinic, Rochester, MN, ³Hennepin County Medical Center, Minneapolis, MN, ⁴UCSF Medical Center, San Francisco, CA, ⁵Johns Hopkins University, Baltimore, MD
*Purpose: The growing end stage kidney disease burden paired with substantial rates of obesity in the United States (US) has prompted increased approval of obese…
2022 American Transplant Congress
The New Heart Allocation Policy Has Increased Listing by Exception
J. R. Golbus¹, Y. Ahn², B. K. Nallamothu¹, M. N. Walsh³, D. Zaun², A. Israni², M. Colvin¹
¹University of Michigan, Ann Arbor, MI, ²Hennepin Healthcare Research Institute, Minneapolis, MN, ³Ascension St. Vincent Heart Center, Carmel, IN
*Purpose: The new heart allocation policy (October 2018) expanded the number of listing statuses and established a national review board for exception requests in an…